Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
The bottom line: Tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy) in clinical trials — but semaglutide has a longer track record, is more widely available through compounding pharmacies, and may work better for some patients. The right choice depends on your health goals, budget, and medical history.
Both semaglutide and tirzepatide are injectable GLP-1 medications that have transformed obesity treatment. They work by mimicking hormones that regulate appetite and blood sugar — but there’s one critical difference: tirzepatide also targets GIP receptors, giving it a dual mechanism that appears to enhance weight loss results.
Semaglutide vs Tirzepatide: At a Glance
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Brand Names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Drug Class | GLP-1 Agonist | GLP-1 + GIP Dual Agonist |
| Average Weight Loss | ~15% body weight | ~20–22% body weight |
| Injection Frequency | Once weekly | Once weekly |
| FDA Approved (Weight Loss) | ✅ Yes (Wegovy) | ✅ Yes (Zepbound) |
| Compounded Availability | ✅ Widely available | ⚠️ Limited |
| Starting Cost (Brand) | ~$1,350/month | ~$1,060/month |
| Compounded Cost | ~$199–299/month | ~$249–399/month |
| Years on Market | Since 2017 (Ozempic) | Since 2022 |
How Each Drug Works
Semaglutide: The Established GLP-1
Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone released after eating. By activating GLP-1 receptors, it slows gastric emptying, reduces appetite signals in the brain, and improves insulin sensitivity. It was first approved for type 2 diabetes (Ozempic, 2017) and later for chronic weight management (Wegovy, 2021). For more details, see our Ozempic and Zepbound head-to-head.
The STEP clinical trials showed patients on semaglutide lost an average of 14.9% of body weight over 68 weeks — a landmark result that positioned it as the most effective weight loss medication available at the time.
Tirzepatide: The Dual-Action Newcomer
Tirzepatide takes a more aggressive approach by targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another incretin hormone that works synergistically with GLP-1 to enhance insulin secretion, suppress glucagon, and reduce appetite. This dual mechanism appears to produce significantly greater weight loss than GLP-1 agonism alone.
The SURMOUNT trials showed tirzepatide at the highest dose (15mg) produced average weight loss of 20.9% of body weight — and some patients lost over 25%. These results surpassed anything previously seen in a weight loss medication trial.
Weight Loss Results: What the Trials Show
This is where tirzepatide pulls decisively ahead. Head-to-head comparison data from the SURMOUNT-5 trial (2024) directly compared tirzepatide vs semaglutide for the first time:
- Tirzepatide (10mg and 15mg): Average 20.2% body weight reduction at 72 weeks
- Semaglutide 2.4mg (Wegovy dose): Average 13.7% body weight reduction at 72 weeks
- Tirzepatide advantage: ~47% more weight loss compared to semaglutide
However, there’s an important caveat: clinical trial averages don’t predict individual response. Some patients lose significantly more on semaglutide than the average tirzepatide patient, and vice versa. Biology, gut microbiome, genetics, and lifestyle all influence results.
Side Effects Comparison
Both medications share a similar side effect profile since they both target GLP-1 receptors. The most common side effects are gastrointestinal:
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | Very common (44%) | Very common (31%) |
| Vomiting | Common (24%) | Common (16%) |
| Diarrhea | Common (30%) | Common (23%) |
| Constipation | Common (24%) | Common (35%) |
| Injection site reactions | Uncommon | Uncommon |
| Pancreatitis risk | Rare | Rare |
| Thyroid C-cell tumors | ⚠️ Animal data warning | ⚠️ Animal data warning |
Notably, tirzepatide appears to cause slightly less nausea and vomiting than semaglutide — but more constipation. Both medications carry the same thyroid tumor warning based on rodent studies (not confirmed in humans). Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Cost and Access in 2026
Brand Name Medications
Both Wegovy (semaglutide) and Zepbound (tirzepatide) are expensive without insurance — typically $1,000–1,500/month at retail. With insurance coverage, copays vary widely. Medicare now covers Zepbound for obesity; Wegovy coverage has expanded significantly.
Compounded Versions: The Affordable Alternative
Compounded semaglutide has become widely available through telehealth platforms at dramatically lower prices — typically $199–299/month. These are pharmacy-compounded versions that contain the same active ingredient but are not FDA-approved finished products.
Compounded tirzepatide is available but less common. Following FDA clarification on tirzepatide’s shortage status, availability has been more restricted than semaglutide. Always use a licensed compounding pharmacy through a legitimate telehealth provider.
Our top-rated telehealth providers for GLP-1 medications:
- Brightmeds — Best overall for compounded semaglutide. From $199/month. Check eligibility →
- Medvi — Best value with physician support included. From $149/month.
- TrimRX — Best structured program with regular monitoring.
Which Should You Choose?
Choose Semaglutide If:
- You want the most affordable compounded option ($199/month vs $249+)
- Access through telehealth is your priority — semaglutide is more widely available
- You’ve used GLP-1 medications before and responded well
- Your physician recommends starting with the established option
- You have cardiovascular disease (semaglutide has stronger cardiovascular outcome data)
Choose Tirzepatide If:
- Maximum weight loss is your primary goal
- You’ve tried semaglutide and experienced a plateau or insufficient results
- You have type 2 diabetes (tirzepatide has excellent glucose-lowering data)
- Cost difference is less of a concern
- Your physician has recommended it based on your metabolic profile
Frequently Asked Questions
Can you switch from semaglutide to tirzepatide?
Yes — many patients who plateau on semaglutide switch to tirzepatide. Your physician will typically require a washout period of 1–2 weeks and will restart at the lowest dose of tirzepatide to minimize side effects. The transition should always be medically supervised.
Is tirzepatide better than semaglutide for everyone?
Not necessarily. Clinical trials show tirzepatide produces greater average weight loss, but individual responses vary significantly. Some patients lose more weight on semaglutide, and others find tirzepatide’s side effect profile harder to tolerate. Cost and access are also important factors.
Are compounded versions of semaglutide and tirzepatide safe?
Compounded GLP-1 medications from licensed 503B compounding facilities and state-licensed pharmacies are legal and widely used. They contain the same active ingredients as brand-name products. The risks arise from unregulated sources — always use a telehealth provider that sources from licensed pharmacies and provides physician oversight.
Which drug works faster?
Both medications begin producing weight loss within the first 4–8 weeks, but full effects develop over 3–6 months as doses increase. Tirzepatide patients tend to see larger total results over the same timeframe due to its dual mechanism, but the onset of action is similar for both.